Valter Longo

Valter Longo earned his PhD in biochemistry at UCLA in 1997, studying antioxidant enzymes and anti-aging genes under Joan Valentine, then completed postdoctoral training under Caleb Finch at the University of Southern California [1]. He is now the Edna M. Jones Professor of Gerontology and Biological Sciences at USC and directs both the USC Longevity Institute and the Longevity and Cancer Program at Milan's IFOM Institute of Molecular Oncology [1].

Longo's research centers on the fasting-mimicking diet, a five-day, low-calorie (roughly 800 to 1,100 kcal per day), low-protein, plant-based eating plan he argues reproduces some of the metabolic effects of water-only fasting while still providing food [1]. In February 2024, USC's Leonard Davis School reported that participants who completed multiple cycles of the diet across two clinical studies showed a reduction in biological age of 2.5 years on average, measured using a validated biological-age method developed by Morgan Levine's group [2]. USC's own disclosure on that same page states plainly that Longo is the founder of and holds an ownership interest in L-Nutra, that L-Nutra's packaged food products (sold as ProLon) are the ones used in the studies, and that USC itself holds an ownership interest in L-Nutra with the potential to receive royalty payments from it [2].

Longo founded L-Nutra to commercialize the fasting-mimicking diet as a packaged product; the company's own site describes its mission as "turning sick care into health care" and states that Longo has authored roughly 150 scientific papers and the bestselling book The Longevity Diet [3]. L-Nutra closed a $47 million growth-investment round in 2023, according to a company press release, reflecting the scale of the commercial operation built around Longo's academic research [1].

The conflict-of-interest structure here is direct and disclosed: the same scientist who designed the fasting-mimicking diet protocol also founded, holds equity in, and profits from the only company selling the specific packaged product tested in his published clinical trials. USC's conflict-of-interest disclosure notes this arrangement is "disclosed and managed per USC's conflict-of-interest policies," which is the standard university mechanism for handling founder-conducted trials of a founder's own product, but does not eliminate the underlying commercial interest [2]. Because ProLon is a specific packaged product rather than a generic dietary pattern, independent replication by labs with no L-Nutra affiliation, using a comparable but non-proprietary fasting-mimicking protocol, is the strongest check on whether the reported biological-age effect generalizes beyond Longo's own trials.

Beyond L-Nutra, Longo's broader dietary recommendation is a mostly plant-based diet with fish eaten no more than two or three times per week, combined with time-restricted eating using an 11 to 12 hour daily window, a lower-intensity intervention than the five-day fasting-mimicking cycles his company sells [1]. In 2018 Longo led a USC-Harvard research team that received a $10 million National Institute on Aging grant to study interventions protecting against aging and disease, funding that predates and is separate from L-Nutra's private investment [1].

The plain takeaway: the fasting-mimicking diet has real, published, university-disclosed trial data behind the specific biological-age claim, but the trials were conducted and are promoted by the same person who profits from the only commercial version of the product being tested, and a reader should weight independent replication more heavily than L-Nutra-sponsored studies when judging the size of the effect.